Paul A. Brooke – Chairman of the Board of Directors
Mr. Brooke has served as a member of our Board of Directors since June 2018 and as Chairman of the Board of Directors since July 2018. He was a founder and managing partner of venBio, LLC, a pharmaceutical investment company, from which he retired at the end of 2016. Mr. Brooke was Chairman of the Board of Directors of Alsius Corporation, a medical device company, from June 2007 through its sale in May 2009, and was the Chairman and Chief Executive Officer of a predecessor company from April 2005 to June 2007. Mr. Brooke has been the Managing Member of PMSV Holdings, LLC, a private investment firm, since 1993. He also served as a Senior Advisor to Morgan Stanley & Co. Incorporated from April 2000 to December 2009, and was a Venture Partner at MPM Capital, a venture capital firm specializing in the healthcare industry, from 1997 through 2006. From April 1999 through May 2000, Mr. Brooke served as a Managing Director at Tiger Management LLC. He was a Managing Director and the Global Head of Healthcare Research and Strategy at Morgan Stanley & Co. from 1983 to April 1999. Mr. Brooke is also a director of several privately held companies. Mr. Brooke was selected to serve on our Board of Directors because he has leadership experience and insight into the operations, challenges and complex issues facing healthcare companies gained from his experience as head of healthcare research at a major investment bank and as an investor.

Lindsay A. Rosenwald, M.D. – Director
Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization of numerous public and private biotechnology and life sciences companies. In addition to serving as a director of Caelum, Dr. Rosenwald is Chairman, President and CEO of Fortress Biotech, Caelum’s parent company. Dr. Rosenwald is also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management firm. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.

Michael Spector – President and Chief Executive Officer and Director
Mr. Spector was named President and Chief Executive Officer in January 2017 and has served on our board of directors since March 2017. He joined Caelum from Fortress Biotech, where he leveraged more than 25 years of biotechnology experience to identify emerging and innovative technologies to launch as new biotech and specialty pharmaceutical companies. Prior to Fortress, Mr. Spector served as Senior Vice President, Global Commercial Operations at Iroko Pharmaceuticals. Earlier in his career, he spent 15 years at GlaxoSmithKline in multiple senior management positions, including Vice President and General Manager of GlaxoSmithKline South Africa, where he led the overall business strategy and was elected to run the South African Pharmaceutical Manufacturers Association. Mr. Spector is also a founding member of Windhoek Healthcare, where he launched two specialty pharmaceutical companies: Laurel Pharmaceuticals and North Creek Pharmaceuticals. Mr. Spector holds an M.B.A. from Rider University in Lawrenceville, N.J., where he serves on the Business and Scientific Advisory Boards, and a B.S. in biology from the University of Pittsburgh. He also serves on the Board of Directors of Jacaranda Health, a nonprofit organization that seeks to transform maternal and neonatal healthcare in East Africa.

David J. Barrett, C.P.A. – Director
Mr. Barrett has served on our Board of Directors since July 2018.  He has been the Strategic Advisor Role at Assembly Biosciences, Inc. since March 8, 2018. Previously he was Chief Operating Officer from February 10, 2015 to March 8, 2018 and Chief Financial Officer from July 2010 to March 8, 2018 at Assembly Biosciences, Inc. Mr. Barrett was also Principal Accounting Officer at Assembly Biosciences, Inc. till 2018. From April 2006 to September 2009, He served as Chief Financial Officer of Neuro-Hitech, Inc. From September 2003 to April 2006, he served as the Chief Financial Officer and Vice President of Finance of Overture Asset Managers and Overture Financial Services, which, at the time, was a start-up asset management firm that assembled investment products and platforms to distribute turnkey and unbundled investment solutions to financial intermediaries and institutional investors. From July 1999 to September 2003, he served as a Manager at Deloitte & Touche, LLP. He served as Director of Fortress Biotech, Inc. (formerly known as Coronado Biosciences, Inc.) from May 2011 to July 15, 2015. Mr. Barrett is a Certified Public Accountant. Mr. Barrett received his B.S. in Accounting and Economics in May of 1998 and his M.S. in Accounting in May of 1999 from the University of Florida.  Mr. Barrett has been selected to serve on our Board of Directors based on his experience, including his extensive experience in global biotechnology and the pharmaceutical industry.

Kenneth W. Cappell – Director
Mr. Cappell began serving on our Board in June 2017. He is currently a Director of Arotech Corporation and has been an Adjunct Professor of Accounting at Baruch College since Fall of 2015.  For the 2014-2015 academic year, he served as an Adjunct Professor of Accounting at Yeshiva University. From 1987 until 2014, Mr. Cappell was a partner of PricewaterhouseCoopers LLP (“PwC”) and its predecessor firms, first as an audit partner (through 2000), then as a regional leader of Internal Audit Services (through 2010), and finally as Managing Partner of Strategic Development for PwC’s Risk Assurance practice (through his retirement in 2014). Mr. Cappell has worked with public companies in a variety of industries, including consumer and industrial products, financial services and entertainment. He has advised public company audit committees on diverse topics and has served as the de facto internal audit director at several companies. Mr. Cappell is a member of AICPA and the New York State Society of CPAs. Mr. Cappell has a B.A. in Economics from Yeshiva University and an M.B.A. in Finance from the NYU Stern School of Business.

Martin Goldman, M.D. – Director
Dr. Goldman began serving on our Board in June 2017.  He is a chaired professor, Vice Chair for Education, Program Director of the Academic Program Training and Associate Director of Cardiology at a major academic medical center in New York City . He also has a large referral practice in clinical cardiology.  He holds a certifications in internal medicine and cardiovascular disease from the American Board of Internal Medicine.  Dr. Goldman received his M.D. at Albert Einstein College of Medicine and completed his internship and residency in Internal Medicine at Brigham and Women’s Hospital at Harvard Medical School . He did his cardiology fellowship and advanced cardiac imaging at Mount Sinai, NYC. He has published over 200 scientific articles.

William Natbony – Director
Mr. Natbony has served on our Board since June 2017.  He is the CEO and Executive Chairman of the Zander Ridge Group, a private family office, and previously was the CEO and Executive Chairman of Tigris Group Inc., a diversified multi-billion dollar family office. Prior to joining Tigris, Mr. Natbony was a senior partner at the international law firm of Katten Muchin Rosenman LLP and was listed in Leading Lawyers in America, New York Super Lawyers and Best Lawyers in America. Mr. Natbony currently holds directorships at Gabriel Resources Ltd., a resources company listed on the Toronto Stock Exchange, Electrum Ltd., a privately-held gold exploration company, Sunshine Silver Mining & Refining Corporation, a privately-held silver exploration and development company, and Panthera Corp. and the Orianne Society, charities that support wildlife conservation. Mr. Natbony holds a J.D. and an LL.M. (in Taxation) from New York University and has been a member of the New York Bar since 1976.

Jeffrey Paley, M.D. – Director
Dr. Paley joined our Board of Directors in June 2017. Dr. Paley has been an active clinician and consultant in the healthcare industry for the past 18 years, during which time Dr. Paley has consulted for over 30 analysts and portfolio managers in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology arenas, reviewing the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices. Prior to his work for the buy-side, Dr. Paley consulted directly for several biotechnology and specialty pharmaceutical companies. Dr. Paley founded Access Medical Associates in 2003, after spending five years on the full-time academic faculty of Weill Cornell Medical College, where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. At Weill Cornell, Dr. Paley was a Principal or Co-Principal Investigator on several studies of diabetes, hypertension, and cholesterol disorders, including the landmark ACCORD study of intensive hyperglycemia, hypertension and hyperlipidemia management. He has served as a Director of Kellbenx, Retrophin and Remote Radiology Inc. and currently serves as a Director of Avenue Therapeutics, Inc., Kalytera Therapeutics, Inc. and Immune Pharmaceuticals, Inc.  Dr. Paley trained at Harvard Medical School and completed a residency in Internal Medicine at Massachusetts General Hospital. Dr. Paley has been selected to serve on our Board of Directors based on his experience, including his experience in medicine and clinical trials and in serving as a director of other public companies.